A moral obligation to those in need and the onset in Europe of diseases traditionally found in the developing world are just two reasons why the EU should be driving investment in neglected diseases, according to Rosa Castro, senior advocacy officer at Deutsche Stiftung Weltbevölkerung, an international non-profit development organization.
Priority review vouchers (PRVs) similar to those issued by the US Food and Drug Administration could prove a key pull investment tool to develop new treatments and get them to patients, said Costa at
Key Takeaways
-
There are no pull incentives for neglected disease research in the EU.
-
Priority review vouchers like those issued by the US FDA could prove successful as incentives
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?